- Science
- Clinical Trials
- Guide to Clinical Trials Your participation makes a difference
- Clinical Trials in Children Designed to improve kids' health
- Data and Results Sharing our Results
- Integrity and Transparency Building Trust
- Diversity Equity and Representation
- Plain Language Study Results Trial Result Summaries
- Expanded Access & Compassionate Use Possible Treatment Options
- Find a Trial
- Areas of Focus
- Rare Disease Smaller populations but big impact
- Internal Medicine Extending lifespans worldwide
- Inflammation & Immunology Treatment at the molecular level
- Vaccines Preventing the spread of infections
- Oncology The science of optimism
- Anti Infectives Combatting an evolving risk
- Areas of Innovation
- Gene Therapy Breakthroughs become treatments
- Medicinal Sciences The next generation of science
- Precision Medicine Developing tailored medicines
- Maternal Immunization Protecting newborns at the start
- mRNA Technology Unleashing the next wave of scientific innovations
- Diseases & Conditions
- Coronavirus Resources
- Product Pipeline
- Research Sites
- Clinical Trials
- Products
- How Drugs are Made
- Branded vs. Generic Learn the difference
- Biologics & Biosimilars Cures found in nature
- Commitment to Quality Maintaining the highest standards
- Global Supply Strategic manufacturing locations
- Manufacturing Sites Where medicine is made in the U.S.
- Medicine Safety
- Health Literacy Learning to be well
- Treatment Choices Learning about treatment decisions
- Partnering With Patients Helping others by reporting side effects
- Tips for Patients Preventing medication errors
- Reporting Adverse Events
- Counterfeiting Preventing medication errors
- Product Safety
- Product List
- Product Contacts
- PfizerPro for Professionals
- Patient Assistance Programs
- Distributors
- How Drugs are Made
- Stories
- Newsroom
- About
- People
- Executives Our senior-most leadership
- Board Members The people steering our company
- Scientists Our experts making discoveries
- Patient Stories Our patients
- Colleague Stories Our colleagues
- Responsibility
- Ethics & Compliance Each of us is responsible
- Responsible Business Breakthroughs that change patients’ lives
- Patient Advocacy & Engagement Putting Patients First
- Global Impact Meeting urgent needs worldwide
- Diversity, Equity, and Inclusion Everyone has something to offer
- Environmental Sustainability Our responsiblity to the environment
- Human Rights Furthering dignity and worth
- Health & Safety
- Intellectual Property The benefits of fair competition
- EHS Governance
- Misinformation
- Programs & Policies
- Grants Support for independent research
- Political Partnership Supporting like-minded organizations
- Working with Healthcare Professionals Collaboration to improve lives
- Prescription Value & Pricing How to lower patient costs
- Privacy Principles Commitment to personal data privacy
- Ready for Cures Improving Access to Medicines
- Transparency in Grants Committed to Disclosure
- Policy Positions
- Investors
- Investors Overview Information for stockholders
- Why Invest Why to join us in our mission
- Events & Presentations Calendar of upcoming events
- Financial Reports Quarterly reports and more
- Investor News Announcements about our performance
- Stock Information Charts and data
- Shareholder Services Information on stock transactions
- Corporate Governance
- Corporate Governance Overview Gaining insight into our performance
- Board Committees & Charters Defining the corporate structure
- The Pfizer Board Policies Ensuring ethical leadership
- Corporate Governance FAQs Learn more about our approach
- Contact Our Directors Email any of our Directors
- Purpose
- History
- Careers
- Partners
- People
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis (OCTAVE)
A Multi-Center, Open-Label Study of CP-690,550 in Participants With Moderate to Severe Ulcerative Colitis
Category & Conditions: Immune System Diseases and Conditions
Medicine: Xeljanz (tofacitinib)
ClinicalTrials.gov Identifier (NCT): NCT01470612
Protocol ID: A3921139
PrintDownloadOpen Plain Language Summary Result: Click here